- Home
- NPCE vs MRVI Comparison
NPCE vs MRVI Comparison
Compare NPCE & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCE
- MRVI
- Stock Information
- Founded
- NPCE 1997
- MRVI 2014
- Country
- NPCE United States
- MRVI United States
- Employees
- NPCE N/A
- MRVI N/A
- Industry
- NPCE Medical Specialities
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- NPCE Health Care
- MRVI Health Care
- Exchange
- NPCE Nasdaq
- MRVI Nasdaq
- Market Cap
- NPCE 292.9M
- MRVI 371.8M
- IPO Year
- NPCE 2021
- MRVI 2020
- Fundamental
- Price
- NPCE $9.15
- MRVI $2.42
- Analyst Decision
- NPCE Strong Buy
- MRVI Hold
- Analyst Count
- NPCE 6
- MRVI 10
- Target Price
- NPCE $16.67
- MRVI $5.84
- AVG Volume (30 Days)
- NPCE 205.3K
- MRVI 1.5M
- Earning Date
- NPCE 08-12-2025
- MRVI 08-11-2025
- Dividend Yield
- NPCE N/A
- MRVI N/A
- EPS Growth
- NPCE N/A
- MRVI N/A
- EPS
- NPCE N/A
- MRVI N/A
- Revenue
- NPCE $88,570,000.00
- MRVI $219,830,000.00
- Revenue This Year
- NPCE $22.13
- MRVI N/A
- Revenue Next Year
- NPCE $6.07
- MRVI $7.23
- P/E Ratio
- NPCE N/A
- MRVI N/A
- Revenue Growth
- NPCE 23.32
- MRVI N/A
- 52 Week Low
- NPCE $5.45
- MRVI $1.67
- 52 Week High
- NPCE $18.98
- MRVI $9.60
- Technical
- Relative Strength Index (RSI)
- NPCE 51.74
- MRVI 49.60
- Support Level
- NPCE $8.61
- MRVI $2.28
- Resistance Level
- NPCE $8.99
- MRVI $2.47
- Average True Range (ATR)
- NPCE 0.53
- MRVI 0.14
- MACD
- NPCE 0.11
- MRVI -0.01
- Stochastic Oscillator
- NPCE 75.00
- MRVI 27.45
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.